<DOC>
	<DOC>NCT03026933</DOC>
	<brief_summary>To examine variation rate of Non-HDL with KI1107 comparison Rosuvastatin monotherapy.</brief_summary>
	<brief_title>Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled</brief_title>
	<detailed_description>Study design: Randomly assigned to two groups(KI1107 or Rosuvastatin monotherpy) after 4 weeks run-in period and prescribed KI1107 or Rosuvastatin for 8 weeks.</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Inclusion criteria: Screening Visit Age: 1980 High risk for cardiovascular disease according to NCEP APT III TG≥130mg/dL and 160mg/dL&gt;LDLC≥100mg/dL for subjects who were not taking statins for 4 weeks 500mg/dL&gt;TG≥200mg/dL and LDLC&lt;110mg/dL for subjects who were taking statins for 4 weeks Baseline Visit 500mg/dL&gt;TG≥200mg/dL LDLC&lt;110mg/dL Reduction of LDLC dompairng screening visit Exclusion criteria: The patient has histories of acute artery disease within 3 months The patient has histories of operation revasculatiation or aneurysm within 6 months The patient has histories of Unexplained myaliga or diagnosed myalgia or rhabdomyolysis The patient has histories of Effectable disease to the procedrue and clinical trial result</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>